Macrosalb

Macrosalb, the active ingredient in Macrosalb, is a radiopharmaceutical presented as a kit for intravenous injection for intravenous use. It is employed in diagnostic imaging to visualize physiological processes in patients.

GNH USA supplies Macrosalb as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Macrosalb is a radiopharmaceutical used in nuclear medicine imaging to assess organ function and disease processes. - Oncology imaging: helps detect and stage malignant tumors. - Cardiac perfusion imaging: evaluates myocardial blood flow. - Renal function assessment: visualizes renal plasma flow and filtration.

Administration of radiopharmaceuticals can be associated with adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild discomfort at the site of intravenous administration. - Nausea: transient feeling of queasiness shortly after injection. - Headache: mild headache that resolves without intervention.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that may need monitoring. - Radiation‑induced tissue injury: localized damage from emitted radiation in rare cases.

Prior to using Macrosalb, several safety considerations should be observed. - Patient screening: assess for known hypersensitivity to radiopharmaceutical components. - Pregnancy assessment: avoid use in pregnant patients unless the diagnostic benefit outweighs potential risk. - Renal function: evaluate kidney function before administration. - Concurrent imaging agents: schedule an adequate interval between other radiotracers or contrast media. - Radiation safety: follow ALARA principles to minimize exposure to staff and patient. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Radiopharmaceuticals may interact with other agents that affect imaging quality or biodistribution.

Major Interactions (Avoid): - Concurrent administration of other radiopharmaceuticals: may cause overlapping radiation fields. - Iodinated contrast agents: can interfere with image interpretation. - Chemotherapeutic agents affecting renal clearance: may alter biodistribution.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may affect cardiac uptake in perfusion studies. - Thyroid hormone therapy: can modify thyroid imaging results. - Antihistamines: may mask mild allergic reactions.